Page 104 - Read Online

Valković et al. J Cancer Metastasis Treat 2022;8:16 https://dx.doi.org/10.20517/2394-4722.2021.208 Page 7 of 7

independent predictors of survival in patients with diffuse large B-cell lymphoma. Acta Haematol 2016;136:52-61. DOI PubMed
8. Valković T, Babarović E, Lučin K, et al. Plasma levels of osteopontin and vascular endothelial growth factor in association with
clinical features and parameters of tumor burden in patients with multiple myeloma. Biomed Res Int 2014;2014:513170. DOI
PubMed PMC
9. Saeki Y, Mima T, Ishii T, et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J
Haematol 2003;123:263-70. DOI PubMed
10. Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma
undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT. Haematologica
2018;103:890-7. DOI PubMed PMC
11. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of
extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325-30. DOI
PubMed
12. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison
to bone-related extramedullary relapse. Haematologica 2014;99:360-4. DOI PubMed PMC
13. Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma: a review of 57 autopsied cases. Cancer
1969;23:167-74. DOI PubMed
14. Deng S, Xu Y, An G, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival:
a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk 2015;15:286-91. DOI PubMed
15. Mulligan G, Lichter DI, Di Bacco A, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent
bortezomib therapy. Blood 2014;123:632-9. DOI PubMed PMC
16. Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk
with lenalidomide-bortezomib combinations. Br J Haematol 2015;169:843-50. DOI PubMed
17. Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 Regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like
transcriptional activation. Cell Rep 2015;12:622-35. DOI PubMed PMC
18. Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone
marrow microenvironment. Blood 2012;119:1468-78. DOI PubMed PMC
19. Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary
myeloma. Br J Haematol 2002;116:273-7. DOI PubMed
20. Hedvat CV, Comenzo RL, Teruya-Feldstein J, et al. Insights into extramedullary tumour cell growth revealed by expression profiling
of human plasmacytomas and multiple myeloma. Br J Haematol 2003;122:728-44. DOI PubMed
21. Montefusco V, Gay F, Spada S, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients
treated with new drugs. Haematologica 2020;105:193-200. DOI PubMed PMC
22. Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann
Hematol 2017;96:73-80. DOI PubMed
23. Sfiridaki A, Miyakis S, Pappa C, et al. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with
multiple myeloma. J Hematol Oncol 2011;4:22. DOI PubMed PMC
24. Cerny J, Fadare O, Hutchinson L, Wang SA. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma.
Eur J Haematol 2008;81:65-9. DOI PubMed
25. Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003;101:1715-7.
DOI PubMed